The co. is a bit slow putting this out... The Female Health Company Presents New Abstract
Abstract Entitled "FC2 Dual Protection, Non-Hormonal, Latex Free Female Condom"
CHICAGO, April 11, 2016 (GLOBE NEWSWIRE) -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the creation of a new abstract entitled "FC2 Dual Protection, Non-Hormonal, Latex Free Female Condom" and authored by Brooke Faught, MSN, WHNP-BC; Irwin Goldstein, MD; Mark Martens, MD; Kelli Rodriguez; and Lisa Levin.
On February 25, 2016, the abstract was presented at the International Society for the Study of Women's Sexual Health (ISSWSH) 2016 Annual Meeting in Charleston, South Carolina. The study surveyed women (ages 25-64) regarding their use of the FC2 Female Condom. Results of the survey indicated a very high percentage (82%) would recommend FC2 to others, and the same percentage (82%) stated positive ease of use. The abstract will also be presented at the Academy of Women's Health's "Women's Health 2016: The 24th Annual Congress" taking place from April 14 to April 17, 2016 in Washington, DC.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom(R) (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom(R), including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom(R) is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. |
